Log In
BCIQ
Print this Print this
 

Minirinmelt, Noqdima, desmopressin (Minirin)

  Manage Alerts
Collapse Summary General Information
Company Ferring Pharmaceuticals A/S
DescriptionPeptide-based synthetic analogue of vasopressin
Molecular Target
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentMarketed
Standard IndicationIncontinence
Indication DetailsTreat bedwetting; Treat nocturia due to idiopathic nocturnal polyuria; Treat primary nocturnal enuresis (PNE) in children
Regulatory Designation
PartnerKyowa Hakko Kirin Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/22/2014

Undisclosed

Undisclosed

Undisclosed

06/13/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today